Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury (PREKIT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline) within 48 hours of intravascular contrast administration in the absence of any alternative causes, or a reduction in urine output documented oliguria of less than 0.5 ml/kg per hour for more than six hours.
It is the common cause of new hospital-acquired renal insufficiency. The occurrence of CIAKI may be influenced by pre-existing renal insufficiency, diabetic nephropathy, dehydration, congestive heart failure, concurrent administration of nephrotoxic drugs, or the dose and type of contrast media used. Previous studies have shown the independent effectiveness of several agents in preventing CIAKI.
Even now, hydration is crucial for preventing CIAKI. Since CIAKI is presumed to be caused by free radical generation, N-Acetylcysteine, which is a potent free radical scavenger, is shown to be effective in preventing nephropathy. At the same time, because free radical formation is promoted by an acidic environment, bicarbonate, which alkalinizes renal tubular fluid, has been shown to reduce renal involvement.
These days, some studies have shown that hydration with sodium bicarbonate plus N-Acetylcysteine was effective and safe in the prevention of CIAKI. In these studies, bicarbonate was used for both alkalinizing renal tubular fluid and hydration. However, if we want to do hydration, we can use saline and if we want to alkalinize renal tubular fluid, we might use bicarbonate by bolus injection.
Actually, bicarbonate for hydration is prepared at sterile preparation room in a hospital, which is very cumbersome procedure and increase in cost. This is one of the reasons that bicarbonate for hydration use does not become common with wide clinical application.
In past issues, though it differs depending on the level of the renal dysfunction, the probability of CIAKI was 8-33% when hydration was administered, 5-15% when hydration and N-Acetylcysteine were administered, and 1.8-1.9% when bicarbonate and N-Acetylcysteine were administered.
Thus, we can hypothesize the combination of N-Acetylcysteine and bicarbonate will play a complementary role in preventing contrast-induced nephropathy.
This is the rational for this study.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Kidney Disease |
Drug: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate |
- Development of contrast-induced acute kidney injury [ Time Frame: within 48 hours ] [ Designated as safety issue: Yes ]Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline) within 48 hours of intravascular contrast administration in the absence of any alternative causes, or a reduction in urine output documented oliguria of less than 0.5 ml/kg per hour for more than six hours.
- Requirement of dialysis [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Requirement of hospitalization and death [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 458 |
| Study Start Date: | October 2009 |
| Estimated Study Completion Date: | March 2011 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Physiological Saline and N-Acetylcysteine |
Drug: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days. 154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure. In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure. |
| Active Comparator: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate |
Drug: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days. 154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure. In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure. |
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- serum creatinine more or equal than 1.1mg/dL
- procedures using contrast media
Exclusion Criteria:
- congestive heart failure
- serum creatinine less than 1.1mg/dl
- allergy to contrast media
- preexisting dialysis
- emergency catheterization
- recent exposure to contrast within 2 days of the study
- refuse to entry this study
- PTRA
- dialysis after procedure
Contacts and Locations| Japan | |
| Sapporo Higashi Tokushukai Hospital | |
| Sapporo City, Hokkaido, Japan, 065-0033 | |
| Principal Investigator: | Daisuke Hachinohe, MD | Sapporo Higashi Tokushukai Hospital |
More Information
Publications:
| Responsible Party: | Daisuke Hachinohe, Sapporo Higashi Tokushukai Hospital |
| ClinicalTrials.gov Identifier: | NCT01210456 History of Changes |
| Other Study ID Numbers: | PREKIT-001 |
| Study First Received: | July 11, 2010 |
| Last Updated: | September 27, 2010 |
| Health Authority: | Japan: Institutional Review Board |
Keywords provided by Tokushukai Medical Group:
|
Chronic Kidney Disease Contrast Media Acute Kidney Injury N-Acetylcysteine Bicarbonate |
Additional relevant MeSH terms:
|
Kidney Diseases Acute Kidney Injury Renal Insufficiency, Chronic Kidney Failure, Chronic Urologic Diseases Renal Insufficiency Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents |
Therapeutic Uses Pharmacologic Actions Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes |
ClinicalTrials.gov processed this record on May 16, 2013